EGFR and sarcopenia: In the EGFR-TKI-treated cohort (n = 77), the median OS and PFS for patients with sarcopenia were significantly shorter than those for patients without sarcopenia (OS: 12.7 vs. 28.0 months; PFS: 8.6 vs. 14.1 months, respectively; both p < 0.001; Figures 2B, E).